| Title | Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. | | Author(s) | Anderson AM, Bartlett JA | | Institution | Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. ander097@mc.duke.edu | | Source | Expert Rev Anti Infect Ther 2005 Dec; 3(6):871-83. | | MeSH | Animals
Anti-HIV Agents
Dideoxynucleosides
Drug Combinations
HIV Infections
HIV-1
Humans
Lamivudine
Research Support, N.I.H., Extramural
| | Abstract | The fixed dose combination of abacavir with lamivudine represents a new treatment option for patients infected with HIV. Fixed dose combination abacavir/lamivudine has the convenience of one pill and once-daily dosing. It achieves comparable suppression of plasma HIV RNA with the pill's individual components dosed twice daily and with thymidine analogs combined with lamivudine. The combination is well tolerated, with the potential advantages of less lipoatrophy and fewer metabolic perturbations. However, the abacavir component may cause hypersensitivity reactions, which are reported in up to 8% of patients, and are potentially life threatening. Fixed dose combination abacavir/lamivudine should be considered as a viable treatment option for HIV-infected patients, particularly for those who have otherwise limited nucleoside reverse transcriptase inhibitor choices. | | Language | eng | | Pub Type(s) | Journal Article
Review
| | PubMed ID | 16307500 |
|
